Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer

por Lal-Nag, M, Battis, M, Santin, A D, Morin, P J
Publicado 2012

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

por Santin, A.D., Scheim, D.E., McCullough, P.A., Yagisawa, M., Borody, T.J.
Publicado 2021

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer

por Santin, A D, Bellone, S, Ravaggi, A, Roman, J J, Pecorelli, S, Parham, G P, Cannon, M J
Publicado 2002

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

por Santin, A D, Zhan, F, Cane', S, Bellone, S, Palmieri, M, Thomas, M, Burnett, A, Roman, J J, Cannon, M J, Shaughnessy, J, Pecorelli, S
Publicado 2005

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas

por Bignotti, E, Ravaggi, A, Tassi, R A, Calza, S, Rossi, E, Falchetti, M, Romani, C, Bandiera, E, Odicino, F E, Pecorelli, S, Santin, A D
Publicado 2008

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

por Santin, A D, Zhan, F, Bellone, S, Palmieri, M, Cane, S, Gokden, M, Roman, J J, O'Brien, T J, Tian, E, Cannon, M J, Shaughnessy, J, Pecorelli, S
Publicado 2004

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytoto...

por Bellone, S, Roque, D, Cocco, E, Gasparrini, S, Bortolomai, I, Buza, N, Abu-Khalaf, M, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2012

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

por Todeschini, P, Cocco, E, Bellone, S, Varughese, J, Lin, K, Carrara, L, Guzzo, F, Buza, N, Hui, P, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2011

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

por Schwab, C L, Bellone, S, English, D P, Roque, D M, Lopez, S, Cocco, E, Nicoletti, R, Bortolomai, I, Bonazzoli, E, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Santin, A D
Publicado 2014

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

por Cocco, E, Hu, Z, Richter, C E, Bellone, S, Casagrande, F, Bellone, M, Todeschini, P, Krikun, G, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Buza, N, Pecorelli, S, Lockwood, C J, Santin, A D
Publicado 2010

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

por Cocco, E, Bellone, S, El-Sahwi, K, Cargnelutti, M, Casagrande, F, Buza, N, Tavassoli, F A, Siegel, E R, Visintin, I, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2009

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

por El-Sahwi, K, Bellone, S, Cocco, E, Cargnelutti, M, Casagrande, F, Bellone, M, Abu-Khalaf, M, Buza, N, Tavassoli, F A, Hui, P, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2010

Facteurs de risque de COVID-19 sévère chez des patients drépanocytaires hospitalisés : étude nationale Française chez 319 patients

por Arlet, J.B., Lionnet, F., Khimoud, D., Joseph, L., De Montalembert, M., Garou, A., Cannas, G., Cougoul, P., Guitton, C., Holvoet, L., Odièvre, M.H., Cheminet, G., Bartolucci, P., Santin, A., Bernit, E., De Luna, G.
Publicado 2021

Caractéristiques des patients drépanocytaires infectés par le SARS-CoV-2 en fonction de leur prise en charge ambulatoire ou en hospitalisation : étude nationale chez 536 patients...

por Arlet, J.B., De Luna, G., Khimoud, D., Cheminet, G., Garou, A., Cannas, G., Cougoul, P., Guitton, C., Holvoet, L., Odièvre, M.H., Joseph, L., Santin, A., De Montalembert, M., Bartolucci, P., Bernit, E., Lionnet, F.
Publicado 2021

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

por Bellone, S, Tassi, R, Betti, M, English, D, Cocco, E, Gasparrini, S, Bortolomai, I, Black, J D, Todeschini, P, Romani, C, Ravaggi, A, Bignotti, E, Bandiera, E, Zanotti, L, Pecorelli, S, Ardighieri, L, Falchetti, M, Donzelli, C, Siegel, E R, Azodi, M, Silasi, D-A, Ratner, E, Schwartz, P E, Rutherford, T J, Santin, A D
Publicado 2013